8th AMR Conference 2024 in Basel/Switzerland

Antimicrobial resistance (AMR) is becoming increasingly important, and companies such as Antabio, Aurobac Therapeutics, Basilea, BioVersys, Debiopharm and Roche are making important contributions to combating these problems.

This year's AMR Symposium in Basel exceeded our expectations, and the presence of established players and numerous start-ups confirms the way forward to revitalise the AMR market with new innovative ideas in an overall challenging environment. A big thank you goes to the numerous sponsors and decision-makers from the large and small biotechnology sector and over 600 guests at the symposium.

As a result of the event, it should be emphasised that there are various excellent and committed teams of scientists who are pushing previous boundaries and laying the foundations for bringing innovative and highly effective AMR drugs to the market. It is also encouraging that the political framework is slowly improving and that those responsible are putting the topic of AMR more on their agenda.